Elon Musk’s brain-computer interface startup Neuralink has been valued at nearly $2 billion after completing private funding two years ago. According to Reuters, Neuralink is now valued at about $5 billion (currently about RMB 35.5 billion) after several private deals.
On May 25, Neuralink announced that the company has received approval from the U.S. Food and Drug Administration (FDA) and will then launch its first human clinical study. This means that Neuralink will be implanting their device into the human brain. As a result, there has been a lot of buying by investors which has increased its valuation significantly in recent months.
Experts say it could take years for Neuralink to get a commercial license. Kip Ludwig, former program director for neural engineering at the National Institutes of Health (NIH), said he “optimistically” expects Neuralink to take at least 10 years to commercialize its brain-machine technology, and that the company faces other challenges, including a federal investigation into its handling of animal research. The company also faces other challenges, including a federal investigation into its handling of animal research.
Neuralink sold privately to investors in recent days on the secondary market at a $7 billion valuation, or $55 per share, after human trials were approved, according to an email seen by Reuters, though Reuters could not determine if anyone bought at that offer. neuralink executives and Musk did not respond to requests for comment.
